
Currently, the Cadherin-6 targeting antibody-drug conjugate is undergoing evaluation in a phase 1a/1b clinical trial.

Currently, the Cadherin-6 targeting antibody-drug conjugate is undergoing evaluation in a phase 1a/1b clinical trial.

The agency will now review the novel PCSK9 inhibitor for possible approval in patients with or at high risk of atherosclerotic cardiovascular disease.

Building on a previously granted orphan drug designation, the latest FDA action for amezalpat puts the drug in a position for regulatory approval.

Up to 61% of all non-small cell lung cancer (NSCLC) cases harbor EGFR mutations.

Avacincaptad pegol intravitreal solution is a prescription eye injection used to treat geographic atrophy.

Black women have higher rates of triple-negative breast cancer (TNBC) incidence and mortality than the general US population. Despite this, they are underrepresented in TNBC clinical trials.

Diversity in clinical trials remains important to ensure research data for therapies accurately reflects the diverse patient populations who will use them globally.

Risdiplam is the only approved non-invasive disease-modifying SMA treatment.

Duloxetine offers treatment for various neuro-psychiatric and pain disorders in patients who have difficulty swallowing.

The trend toward higher-potency marijuana could pose additional, unknown risks.

The approval follows the ECHELON-3 study, which enrolled adults with relapsed or refractory large B-cell lymphoma.

Pharmacists can provide resources, monitor medications, and extend compassionate support to patients experiencing mental health challenge.

Reductions in cerebellar volume were associated with cognitive deficits and lower kidney function in those with CKD.

Molly Schiffer, PharmD, BCOP, discusses the logistical, operational, and financial challenges of delivering cellular therapies in the outpatient setting, focusing on CAR T-cell therapy, TIL therapies, and emerging trends in non-oncology applications.

Supplements, such as Prevagen, as well as lifestyle and diet modifications can provide additional support to patients with Alzheimer disease.

The approval marks a significant milestone in the treatment of a rare and aggressive subtype of acute leukemia.

Cytopenic myelofibrosis is characterized by poorer prognosis and more severe anemia and thrombocytopenia compared with proliferative myelofibrosis.

The approval is based on positive clinical trial results that indicated deep and durable reductions in plexiform neurofibroma.

Amazon Pharmacy’s subscription service could cause sale disruptions for traditional retail pharmacies.

Presence of leptomeningeal disease is associated with poorer treatment outcomes and quality of life for patients with breast cancer.

Rezpegaldesleukin is designed to balance the body’s immune system response through activation of regulatory T-cells.

Emerging data indicate that COVID-19 is also characterized by inflammation present in the heart and other organs

If approved, brensocatib will be the first and only approved treatment for bronchiectasis and the first within a new class of medicines, called dipeptidyl peptidase 1 inhibitors.

Pharmacists can recommend vitamin D supplements and vitamin D-rich foods to support healthy pregnancy outcomes.

The decision to end HYPERION (NCT04811092) comes after positive results from an interim analysis of the ZENITH trial (NCT04896008).

Richard Lewis discusses the critical role pharmacists and health care providers play in ensuring safe administration of IVIG for patients with CIDP.

Thalassemia, a chronic blood condition that reduces hemoglobin levels, requires a hands-on approach from pharmacists in patient monitoring and diagnosis.


